Introduction {#Sec1}
============

The aims of liver transplantation (LT) are to increase survival and quality of life in patients with acute liver disease, end-stage chronic liver disease with or without early hepatocellular carcinoma (HCC), and those with certain metabolic diseases affecting the liver or other organs. Over the past 20 years since LT became an established procedure, progress has been impressive \[[@CR1]--[@CR4]\]. The current databases of the European \[[@CR5]\] and American Liver Transplant Registries \[[@CR6]\] show 1-year and 10-year survival rates of over 90 and 60 %, respectively, clearly higher than expected survival if the disease was allowed to run its clinical course.

Although several centers are now reaching 20 years of clinical experience with LT, little information on actual 20-year survival in adult liver transplant patients exists in the literature \[[@CR7]--[@CR9]\]. With many more patients receiving transplants in the 1990s than in the 1980s, and after overcoming the learning curve concerning improvements in surgical techniques, immunosuppression regimens and management of infections, the transplant community can expect a considerable increase in the total number of 20-year LT survivors over the next decade.

The aims of the present study were to retrospectively analyze the clinical outcome of LT survivors followed up for at least 20 years. More specifically, we aimed to determine the incidence of chronic renal dysfunction, arterial hypertension, diabetes mellitus, dyslipidemia, cardiovascular events and de novo tumors. The causes of death during the same period and risk factors of mortality were also analyzed.

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

A retrospective analysis of prospective, longitudinal data, collected at a single center was performed to evaluate 20-year LT survivors. The study group consisted of all adult patients (\>18 years of age) who underwent LT at the Hospital Vall d´Hebron (Barcelona, Spain) between October 1988 and May 1993 with a minimum survival of 20 years post-transplantation. A comparative sub-analysis was performed with patients not alive 20 years after transplantation to identify the causes of death and risk factors of mortality. Median follow-up was 59 months with a range of 0--292 months.

During study period, a Collins solution was used for graft preservation until 1990, and thereafter the University of Wisconsin (UW) in all cases. Bypass or the classical technique was standard until 1991 when it was switched to inferior vena cava preservation in the anhepatic phase. Maintenance immunosuppression regimens consisted of a double regimen of cyclosporine (CyA) and prednisone or a triple-drug regimen that included azathioprine from 1988 to 1995. The routine use of tacrolimus was initiated at our institution in 1993, and it has become the standard maintenance immunosuppressive agent.

Pre-transplant demographic characteristics of recipients, donors, surgery and all post-transplant events and complications during follow-up were analyzed. Recipient characteristics analyzed were: age, sex, indications for transplant, serology, Child-Pugh class, United Network for Organ Sharing (UNOS) status, concomitant diseases (renal dysfunction, arterial hypertension, diabetes mellitus and cardiovascular disease) and primary or retransplantation.

Regarding donor characteristics, we should specify that all of them were deceased donor after brain death. Main donor data studied were: age, gender, cause of death and hepatic steatosis. Surgical variables analyzed were: cold ischemia time (CIT) and warm ischemia time (WIT), presence of portal thrombosis, and intraoperative transfusion.

All post-operative complications arising during follow-up were entered prospectively in a database. Medium- and long-term variables evaluated at different time points (1st, 5th, 10th, 15th and 20th year) were: renal and liver function, incidence of arterial hypertension, diabetes mellitus, dyslipidemia, cardiovascular events, and de novo malignancies.

Definitions {#Sec4}
-----------

CIT was defined as time from cross-clamping until removal of the organ from the ice to implantation commences, and WIT as time of ischemia during graft implantation.

Primary graft dysfunction was defined as poor initial graft function, leading to retransplantation or death during the first week post-transplant. Graft dysfunction was classified according to the highest peak of liver function test during the first 4 days post-transplant \[[@CR4]\]: mild (transaminases \<1,000 IU and prothrombin index \>60 %), moderate (transaminases 1,000--5,000 IU and prothrombin index 30--60 %) and severe (transaminases \>5,000 IU and prothrombin index \<30 %).

Patients were monitored at outpatient clinics and laboratory data were evaluated monthly for the first 3 months and every 3 or 6 months thereafter. Based on laboratory results, we defined post-transplant liver dysfunction as AST/ALT ≥100 IU/L and/or total bilirubin ≥1.5 mg/dL, requiring complete study with Doppler ultrasound and liver biopsy according to our protocol.

Rejection episodes were determined by liver biopsy and graft rejection defined and stratified according to the BANFF criteria \[[@CR10]\]; cytomegalovirus (CMV) infection was diagnosed when viral load exceeded 1,000 copies/mL.

HCV recurrence was diagnosed by liver biopsy in patients with liver dysfunction and who were HCV-RNA-positive, and no protocol liver biopsies were available as no standardized procedure was in place in our follow-up at that time.

Renal function was evaluated by serum creatinine levels and estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD)-4 formula. Renal dysfunction was defined as eGFR \<60 mL/min/1.73 m^2^ \[[@CR11]\]. However, since eGFR data were not always available in our study at that time, pre-transplant renal dysfunction was defined as pre-transplant creatinine levels ≥1.5 mg/dL hepato-renal syndrome or need for dialysis.

The following definitions were applied for the main risk factors of cardiovascular disease:*Arterial hypertension*. Defined as blood pressure \>140/90 mmHg at two following visits according to the European Society of Hypertension criteria \[[@CR12]\].*Diabetes mellitus.* Defined as fasting plasma glucose \>126 mg/dL at two following visits according to the World Health Organization \[[@CR13]\].*Dyslipidemia.* Defined as hypercholesterolemia \>220 mg/dL and hypertriglyceridemia \>200 mg/dL at two following visits.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using SPSS 21.0 software (SPSS, Chicago, IL, USA). Quantitative variables normally distributed were expressed as mean values ± 1SD and those non-normally distributed were expressed as median values (range). Qualitative variables were expressed as proportions. Group comparisons were made by Student's *t* test and Mann--Whitney *U* test for continuous data and the Chi square test with Fisher's correction for categorical data. Differences were considered statistically significant when the *p* value was \<0.05. Survival curves were analyzed using Kaplan--Meier curves. Cox regression was used to assess independent factors associated with overall survival, and deaths in the first year post-transplant were excluded to assess the independent factors associated with long-term survival (\>1 year post-transplant).

Results {#Sec6}
=======

Study population {#Sec7}
----------------

Between 1988 and 1994, 132 patients received 151 orthotopic LT at our center. Twenty-eight of the 132 patients have survived for more than 20 years and comprise the study group.

The primary indications for transplantation are shown in Table [1](#Tab1){ref-type="table"}. The most common indication in the 20-year survivors was HCV cirrhosis, followed by cholestatic cirrhosis (primary and secondary biliary cirrhosis and primary sclerosing cholangitis). Alcoholic cirrhosis and HCC were less frequent indications in 20-year survivors than in non-survivors. Pre-transplant recipient characteristics, donor and surgery data are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Pre-transplant recipient characteristics20-year survivors\
(*n* = 28)Non-20-year survivors\
(*n* = 104)*p*Age (years)54 (24--66)55 (16--66)0.13Gender (male/female)16 (57 %)/12 (43 %)71 (68 %)/33 (32 %)0.93Etiology of liver disease0.04 HCV cirrhosis10 (36 %)35 (34 %) Alcoholic cirrhosis4 (14 %)26 (24 %) Hepatocellular carcinoma2 (7 %)23 (22 %) Cholestatic cirrhosis7 (25 %)5 (5 %) Fulminant failure2 (7 %)6 (6 %) Metabolic cirrhosis--1 (1 %) Budd Chiari--1 (1 %) Others3 (10 %)7 (7 %)ABO identical25 (89 %)99 (95 %)0.24Child-Pugh class0.66 A4 (14 %)10 (10 %) B11 (40 %)37 (35 %) C13 (46 %)57 (55 %)UNOS status0.87 Home24 (86 %)92 (88 %) Hospital1 (4 %)4 (4 %) Intensive Care3 (10 %)8 (8 %)Urgent liver transplant2 (7 %)7 (7 %)0.93Renal dysfunction1 (4 %)13 (13 %)0.17Hypertension1 (4 %)6 (6 %)0.93Diabetes mellitus3 (11 %)12 (12 %)0.90Cardiovascular disease3 (11 %)10 (10 %)0.86*UNOS* United Network for Organ SharingTable 2Donor and surgery characteristics20-year survivors (*n* = 28)Non-20-year survivors (*n* = 104)*p*Age (years)37 (9--64)32 (7--64)0.59Gender (male/female)20 (72 %)/8 (28 %)67 (65 %)/37 (35 %)0.48Cause of death0.60 Cerebrovascular accident14 (50 %)46 (44 %) Cranio-encephalic trauma9 (32 %)44 (42 %) Anoxia3 (11 %)5 (5 %) Others2 (7 %)9 (9 %)Graft steatosis \>20 %2 (7 %)24 (23 %)0.06Cold ischemia time (min)528 ± 155504 ± 1530.07Warm ischemia time (min)61 ± 2070 ± 230.45Portal thrombosis1 (4 %)19 (18 %)0.05Intraoperative transfusion Red blood cells (unit)6 (2--22)8 (2--75)0.006 Fresh frozen plasma (unit)11 (3--28)12 (3--75)0.17 Platelets (unit)5 (0--30)10 (0--54)0.03

Regarding the main post-operative complications (Table [3](#Tab3){ref-type="table"}), recipients surviving 20 years had a lesser tendency to CMV infection (21 vs. 34 %, *p* = 0.15) and biopsy-proven acute rejection (54 vs. 65 %, *p* = 0.25) than non-survivors. Moreover, progression to chronic rejection was slightly significantly lower in 20-year survivors compared to non-survivors (7 vs. 22 %, *p* = 0.06). No vascular complications occurred in 20-year survivors and biliary complications were similar in both groups (21 vs. 25 %, *p* = 0.69). At 1 year post-transplant, renal dysfunction had been present in 50 % of patients who survived for 20 years (vs. 67 %, *p* = 0.21) and liver dysfunction in 18 % (vs. 45 %, *p* = 0.01).Table 3Induction immunosuppression and main post-operative complications20-year survivors (*n* = 28)Non-20-year survivors (*n* = 104)*p*Induction immunosuppression0.61 CyA-St22 (78 %)73 (72 %) Tac-St6 (22 %)19 (19 %) Cya-St-AZA--7 (7 %) St-OKT3--2 (2 %)Ischemia reperfusion injury0.32 Mild13 (47 %)67 (65 %) Moderate11 (39 %)25 (25 %) Severe3 (11 %)7 (7 %) PNF1 (4 %)3 (3 %)CMV infection6 (21 %)36 (34 %)0.15Acute rejection15 (54 %)66 (65 %)0.25Chronic rejection2 (7 %)23 (22 %)0.06Technical complications Artery thrombosis--5 (5 %)0.58 Portal thrombosis--3 (3 %)0.99 Hepatic vein stenosis--1 (1 %)0.99 Biliary complications6 (21 %)26 (25 %)0.69Renal dysfunction at end of the 1st year^a^14 (50 %)42 (67 %)0.21Liver dysfunction at end of the 1st year^b^5 (18 %)30 (45 %)0.01Retransplant3 (11 %)16 (15 %)0.53*CyA* cyclosporine, *St* steroids, *Aza* azathioprine, *Tac* tacrolimus, *PNF* primary non-function, *CMV* cytomegalovirus^a^Defined as estimated glomerular filtration rate \<60 mL/min/1.73 m^2b^Defined as AST/ALT ≥100 IU/L and/or total bilirubin ≥1.5 mg/dL

Long-term complications in 20-year survivors (Table [4](#Tab4){ref-type="table"}) {#Sec8}
---------------------------------------------------------------------------------

Regarding liver function, medians of AST, ALT and total bilirubin at 20 years were 33 IU/L (13--135 IU/L), 27 (11--152 IU/L) and 0.6 mg/dL (0.3--1.1 mg/dL), respectively. Two patients (7 %) with the diagnosis of cirrhotic stage secondary to hepatitis C recurrence presented liver dysfunction at that time.Table 4Evolution over time in 20 year survivors of renal function and liver function, arterial hypertension, diabetes mellitus, dyslipidemia, and immunosuppression (*n* = 28)1st year5th year10th year15th year20th yearLiver function AST (IU/L)28 (10--178)36 (14--160)39 (13--133)32 (14--66)33 (13--135) ALT (IU/L)38 (12--370)53 (10--297)41 (13--205)41 (11--111)27 (11--152) Total bilirubin (mg/dL)0.9 (0.3--2.5)0.7 (0.3--2.2)0.7 (0.4--1.7)0.7 (0.3--2)0.6 (0.3--1.1)Renal function   (eGFR mL/min/1.73 m^2^)60 (18--96)60 (21--112)67 (12--89)57 (12--98)64 (6--144)Arterial hypertension12 (43 %)15 (54 %)18 (64 %)17 (61 %)17 (61 %)Diabetes mellitus4 (14 %)4 (14 %)6 (21 %)6 (21 %)6 (21 %)Dyslipidemia6 (21 %)7 (25 %)12 (43 %)12 (43 %)12 (43 %)Immunosuppression CyA--14 (50 %)13 (46 %)11 (39 %)11 (39 %) Tac4 (14 %)7 (25 %)7 (25 %)5 (18 %)4 (14 %) CyA + St/MMF21 (75 %)6 (21 %)1 (4 %)3 (11 %)3 (11 %) Tac + St/MMF3 (11 %)--3 (11 %)6 (21 %)6 (21 %) Others--1 (4 %)2 (7 %)--1 (4 %) Withdrawal----2 (7 %)3 (11 %)3 (11 %)*AST* aspartate transaminase, *ALT* alanine transaminase, *eGFR* estimated glomerular filtration rate, *CyA* cyclosporine, *St* steroids, *Tac* tacrolimus, *MMF* mycophenolate mofetil

Renal function remained stable during the 20-year follow-up and median eGFR at 20 years was 64 mL/min/1.73 m^2^ (6--144 mL/min/1.73 m^2^). Ten patients (40 %) presented renal dysfunction at that time, and only 1 (4 %) developed chronic kidney failure requiring hemodialysis.

Development over time of the different risk factors known to be associated with cardiovascular disease, including arterial hypertension, diabetes mellitus and dyslipidemia, is shown in Table [4](#Tab4){ref-type="table"}. In summary, at 20 years post-transplant, 61 % had arterial hypertension (72 % were managed with one medication), 21 % diabetes mellitus (50 % with oral antidiabetics, 40 % with insulin and 10 % with diet) and 43 % dyslipidemia (75 % requiring medication). Five patients (18 %) developed some cardiovascular event during follow-up: ischemic cardiomyopathy in 2, atrial fibrillation in 2 and peripheral vascular disease in 1.

Seven patients (25 %) developed de novo tumors: prostate cancer in two patients, laryngeal carcinoma in one, melanoma in one, basal cell carcinoma of the skin in two and squamous cell carcinoma of the skin in one. Four patients developed a second de novo tumor, all skin cancers (basal cell carcinoma in three patients and squamous cell carcinoma in one).

After 20 years of survival, 53 % of the patients remained on anticalcineurin inhibitors in monotherapy, and in only three patients (11 %) could immunosuppression be withdrawn definitively.

Patient and graft survival {#Sec9}
--------------------------

Overall actuarial 5-, 10- and 20-year patient survival rates were 48, 38 and 22 %, and graft survival rates 43, 32 and 20 %, respectively. The survival range among 20-year survivors was 20--24.3 years. Of all the 20-year survivors, 2 had died due to hepatitis C recurrence after surviving 21 years. The causes of death in non-20-year survivors are shown in Table [5](#Tab5){ref-type="table"}.Table 5Causes of death in liver transplant patients during the study period\<1 year (*n* = 41, 39 %)1--5 years (*n* = 41, 39 %)\>5 years (*n* = 22, 22 %)Graft-related Recurrent primary disease  HCV5 (12 %)5 (12 %)**5 (22** **%)**  HCC1 (2 %)5 (12 %)2 (9 %)  HBV1 (2 %)----  Alcohol----1 (5 %)  PSC--1 (2 %)-- Rejection  Acute4 (10 %)1 (2 %)--  Chronic4 (10 %)3 (7 %)1 (5 %) Primary non-function3 (7 %)---- Intraoperative death2 (5 %)---- Arterial thrombosis2 (5 %)4 (11 %)1 (5 %) Biliary complications2 (5 %)----Non-graft-related Medical complications  Infections**13 (32** **%)10 (25** **%)**1 (5 %)  Cardiovascular disease2 (5 %)1 (2 %)**5 (22** **%)**  Gastrointestinal complications--1 (2 %)--  Kidney failure2 (5 %)---- De novo malignancy--**8 (21** **%)**3 (13 %) Accident----2 (9 %) Others--2 (4 %)1 (5 %)The commonest causes of death in each period since transplant are shown in bold*HCV* hepatits C virus, *HBV* hepatitis B virus, *HCC* hepatocellular carcinoma, *PSC* primary sclerosing cholangitis

The overall incidence of retransplant in this series was 14 % (19 patients). Among the 20-year survivors, two were retransplanted within the first year post-transplant owing to primary non-function and chronic rejection and a third was retransplanted due to hepatitis C recurrence after 2 years. Sixteen of the non-20-year survivors were retransplanted: 13 within the first year due to arterial thrombosis \[[@CR4]\], chronic rejection \[[@CR4]\], primary non-function (3 patients) and acute rejection \[[@CR2]\]. The remaining three patients were retransplanted beyond the first year owing to acute rejection \[[@CR1]\], chronic rejection \[[@CR1]\] and arterial thrombosis \[[@CR1]\]. No patients had more than 1 retransplant.

Risk factors of mortality {#Sec10}
-------------------------

The univariate analysis of risk factors associated with mortality is shown in Table [6](#Tab6){ref-type="table"}. In multivariate Cox regression analysis, the perioperative variables showing independent predictive value were: HCC indication (*p* = 0.049, OR 1.60), pretransplant renal dysfunction (*p* = 0.043, OR 1.83) and long WIT (*p* = 0.016, OR 1.68). This Cox regression model also showed diabetes mellitus (*p* = 0.001, OR 6.03) and liver dysfunction (*p* = 0.05, OR 2.29) at 1 year as post-transplant variables independently related to long-term survival.Table 6Main risk factors associated with overall mortality (Cox regression analyses)UnivariateMultivariate*p*ORCI (95 %)*p*ORCI (95 %)Recipient age \>60 years0.7401.070.697--1.663Anti-HCV+0.8390.960.654--1.412HCC0.0631.530.978--2.3950.0491.601.002--2.584Pretransplant renal dysfunction0.0301.901.064--3.4120.0431.831.020--3.292Donor age \>40 years0.2450.780.529--1.177Steatosis \>20 %0.0590.640.407--1.017Portal thrombosis0.2681.320.804--2.192CIT \>8 h0.3010.810.552--1.201WIT \>60 min0.0281.601.052--2.4440.0161.681.103--2.586Severe reperfusion injury0.4900.790.413--1.527CyA induction0.7201.090.665--1.805Risk factors associated with long-term survival (after excluding deaths over 1st year post-transplant) CMV infection0.2771.360.780--2.376 Acute rejection0.1711.450.852--2.468 Chronic rejection0.0052.261.289--3.991 Vascular complications0.0043.201.445--7.103 Biliary complications0.2771.340.786--2.314 Retransplant0.4421.290.673--2.480 Arterial hypertension at 1 year0.0282.011.078--3.765 Diabetes mellitus at 1 year0.0016.943.131--15.3980.0016.032.339--15.574 Dyslipidemia at 1 year0.0013.681.953--6.934 Renal dysfunction at 1 year0.1061.530.913--2.573 Liver dysfunction at 1 year0.0022.201.334--3.6430.0502.291.000--5.261*HCV* hepatitis C virus, *HCC* hepatocellular carcinoma, *CIT* cold ischemia time, *WIT* warm ischemia time, *CyA* cyclosporine, *OR* odds ratio,*CI* confidence interval

Discussion {#Sec11}
==========

Over two decades have elapsed since LT became accepted as a therapeutic option for end-stage liver disease \[[@CR1]\]. During this period, more than 250 centers performing LT have emerged throughout the world and many have reported periodically on their series \[[@CR2], [@CR3], [@CR14]--[@CR17]\] in terms of patient and graft survival; however, little has been reported on the long-term complications of this procedure and the risk factors of late mortality \[[@CR7]--[@CR9], [@CR14]\]. As our transplant program started 25 years ago, we decided to evaluate the outcome of our 20-year survivors in an attempt to understand their morbidity and the main causes of death with a view to developing strategies that may improve the long-term outcome in future series.

For analysis of our results, we should point out that all LT performed between the start of our program in 1988 and 1993 were included. We did not record our experience in pediatric liver transplants, a significant difference compared with other series, and which could explain the lower 20-year LT survival rates in the present analysis (21 %) versus the 50 % in other studies \[[@CR2], [@CR5], [@CR7]\]. Recently, Shoening et al. \[[@CR9]\] showed patient and graft survival of 52 and 47 %, respectively, at 20 years post-adult LT. However, it should be considered that only 10 % of patients were HCV-positive in their study compared to 34 % in our series.

On analyzing the characteristics of our 20-year survivors, hepatitis C cirrhosis was the main indication in both groups (36 vs. 34 % in non-20-year survivors), cholestatic cirrhosis was the second leading indication in 20-year survivors (25 %) and alcoholic cirrhosis (24 %) followed by HCC (22 %), the second and third leading indications in non-20-year survivors. The younger age of donors in that period could explain the unexpected long-term survival from hepatitis C in 20-year survivors. Moreover, lesser graft steatosis \>20 % (*p* = 0.06), incidence of portal thrombosis (*p* = 0.05) and intraoperative multi-transfusion (*p* = 0.03) were observed in 20-year survivors. These factors had been shown to be associated with worse survival after LT in previous studies \[[@CR18]--[@CR20]\].

Regarding the immediate post-transplant period, CyA was the principal induction immunosuppressive agent in both groups during the transplant era reported here. Although the overall incidence of acute rejection was similar in both groups, it more frequently progressed to chronic rejection in the non-20-year survivors group (22 vs. 7 %, *p* = 0.06), thus reducing patient survival, as reported previously \[[@CR7], [@CR21], [@CR22]\]. Consistent immunosuppression levels and avoidance of transition to chronic rejection without increasing the risk of infection have long been critical goals of post-transplant care, mainly during the early years of LT and, therefore, the learning curve in immunosuppression management. Biliary complications are well known to impair both short- and long-term outcomes after LT \[[@CR2], [@CR3], [@CR7], [@CR23]\]; however, no significant differences were observed in 20-year survivors compared to non-20-year survivors in our series.

Chronic renal dysfunction is a frequent complication after LT and progresses to end-stage renal disease, requiring hemodialysis in 4--8 % of cases. Sheiner et al. \[[@CR24]\] reported that, although follow-up creatinine clearance rates reflected renal insufficiency in 70 patients (79.5 %), only 4 developed chronic renal failure requiring hemodialysis 5 years after LT. Similar results were reported recently in a Spanish series \[[@CR14]\] where more than a third of the patients had chronic renal impairment after 10 years of survival but only 6 % developed end-stage renal failure. These data are confirmed in our long-term survivors: 50 % had renal dysfunction at 1 year post-transplant and 40 % at 20 years with 4 % being on hemodialysis. The renal function stabilization at the end of follow-up reflects the less immunosuppression required or even switched to other proven less nephrotoxic immunosuppressors such as mammalian Target of Rapamycin (mTOR) inhibitors or mycophenolate mofetil in monotherapy \[[@CR25]--[@CR30]\].

Arterial hypertension, diabetes mellitus and dyslipidemia were the most common medical complications in our 20-year survivors, and their prevalence increased throughout follow-up, reaching 61, 21 and 43 %, respectively. These results are comparable to those published in the literature \[[@CR8], [@CR9], [@CR14], [@CR24], [@CR31], [@CR32]\]. Moreover, Rubin et al. \[[@CR14]\] recently estimated that the prevalence of arterial hypertension, diabetes mellitus and dyslipidemia in LT recipients at 10 years post-transplant was increased twofold compared to the general population. Close surveillance to treat promptly these events is required; moreover, better management of immunosuppressive drugs will be reflected in a lower incidence of metabolic complications in future series \[[@CR33]--[@CR36]\].

The incidence of de novo tumors in our 20-year survivors was 25 %, higher than that published in the literature \[[@CR9], [@CR14]\] and mainly due to skin cancer which is more prevalent in Mediterranean areas, and even higher than that observed in the general population \[[@CR37]--[@CR39]\]. For this reason, long-term screening protocols for skin tumors should be mandatory in LT patients.

The main cause of death in our non-20-year survivors was infections (32 %) in the first year and between 1 and 5 years post-transplant (25 %). These data are consistent with findings in other cohorts \[[@CR2], [@CR40], [@CR41]\], as recently reported by Schoening et al. \[[@CR9]\], who showed that 21 % of deaths attributed to early or late infections occurred more often during the first year post-transplant. Once again, no doubts existed as to the cause--effect of over-immunosuppression during the first era of LT programs. Schoening et al. \[[@CR9]\] also reported de novo tumors as the main cause of death within the second decade post-LT (26 %), whereas it was the second cause of death (21 %) in our study. This could be explained by the different etiologies for LT in each group, if we consider that alcohol-induced cirrhosis, strongly related to neoplastic diseases, was the first indication for LT in the German group, and hepatitis C in our series. In view of this, hepatitis C recurrence was the main cause of death (22 %) together with cardiovascular disease (22 %) in the last years of follow-up, as expected due to the long-term follow-up-related nature and similar to results reported by other groups \[[@CR42], [@CR43]\].

Regarding risk factors of mortality, recent papers \[[@CR2], [@CR3], [@CR7], [@CR9]\] have described recipient age and gender, urgent indication, HCC, CIT, retransplant and biliary complications as major variables affecting long-term survival. Interestingly, recipient age or gender did not affect survival in this study, even considering that our cohort was older than those described in the literature. The only determinant pre-transplant factors for long-term survival in our series were HCC and renal dysfunction, owing to the malignant nature of the former and as a symptom of pre-transplant recipient "poor status" in the latter, as historically reported \[[@CR4], [@CR44]--[@CR46]\]. The low median age of our grafts at that time could have neutralized the CIT effect in our results. However, longer WIT proved to be an independent risk factor, as Busuttill et al. \[[@CR3]\] had already demonstrated. With respect to post-transplant variables, liver dysfunction and diabetes mellitus at the end of the first year post-transplant were significant independent risk factors of mortality. This would appear to be normal considering that a graft, which after 1 year of survival is not able to function correctly mainly because of HCV recurrence and acute rejection, is less likely to survive in the long-term. Diabetes mellitus has also been linked to hepatitis C recurrence and described as one of the major cardiovascular risk factors, two powerful reasons that explained our results \[[@CR35], [@CR47], [@CR48]\].

In conclusion, our study adds more information on outcome in LT after 20 years of follow-up, taking into account the cumulative experience acquired since our program started in the late 1980s, the different technical approach, the aggressive immunosuppression protocols used and even that one-third of our recipients were hepatitis C-positive. Although LT offers acceptable long-term survival, the significant comorbidities presented by recipients (arterial hypertension, diabetes mellitus, dyslipidemia, de novo tumor, hepatitis C recurrence) oblige us to adopt early prevention and therapeutic measures and modify the management of immunosuppression to minimize long-term morbidity and improve long-term survival. However, if prolonged life is expected in our LT patients and considering the current changes in immunosuppression (no steroids, calcineurin inhibitors minimization, mTOR inhibitors), type of donors (expanded criteria, living donors) and the new antiviral therapies, further studies will be required in coming years to reassess long-term outcome.
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